Yes Kory as I have worked many years in labs calculating test results and a 0.5 endpoint always goes to the benefit of the drug trial results as indicated.The difference is not worth noting as the parameters would not hinder any outcome becoming a positive event for the company.I believe most know what I'am referring to on the topic of testing results.
"a 0.5 endpoint always goes to the benefit of the drug trial results as indicated." Are you an idiot? Most drugs fail.. They also have 0% impact on RMTI's data coming up. Do you know the phase 2b trial did not hit it's endpoint? Granted it was 1.0, but still your post is obv vague b/c you are clueless and trying to pump.. maybe do some DD on the actual stock